Diffuse Large B-Cell Lymphoma Clinical Trials

A listing of 33 Diffuse Large B-Cell Lymphoma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Diffuse Large B-Cell Lymphoma

13 - 24 of 33

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 33 active clinical trials seeking participants for Diffuse Large B-Cell Lymphoma research studies. The states with the highest number of trials for Diffuse Large B-Cell Lymphoma participants are California, Ohio, New York and Texas.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Research Study

Recruiting

Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Sinusitis

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Stroke Clinical Study

Recruiting

A clinical study for people that suffer with Stroke

Conditions:

Stroke

Learn More

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

NCT06977711

Recruiting

This study is developed by the investigator and is a, phase I, single arm, clinical trial that will enroll subjects with untreated diffuse large B-cell lymphoma (DLCBL) at high risk for poor outcome. The types of treatments given will be shared with participants. The aims are: 1. To assess the safety and how well the participants tolerate the treatment 2. Assess the response of the tumor to treatment to estimate complete response 3. Assess the response of the tumor to treatment to estimate pro... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/30/2025

Locations: University Hospital System, San Antonio, Texas +1 locations

Conditions: Diffuse Large B-cell Lymphoma

Learn More ›

Hyperfractionated Dual Equivalent Fractionated Radiation Therapy

NCT06898905

Recruiting

This study evaluates the feasibility and safety of a novel method for comparing the effectiveness of hypofractionated versus hyperfractionated radiation therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) undergoing T-cell redirection therapies (CAR T-cell therapy or bispecific antibodies).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/21/2025

Locations: Yale University, New Haven, Connecticut

Conditions: Diffuse Large B-Cell Lymphoma

Learn More ›

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017

Recruiting

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Confirmation (Part 1) and Efficacy Expansion (Part 2) and will enroll participants who are at least 18 years of age with rrDLBCL. The hypotheses are: ZV in combination with rituximab, gemcitabine, and oxal... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/18/2025

Locations: Bass Medical Group ( Site 0166), Walnut Creek, California +108 locations

Bass Medical Group ( Site 0166), Walnut Creek, California

Innovative Clinical Research Institute ( Site 0122), Whittier, California

Boca Raton Regional Hospital- Lynn Cancer Institute ( Site 0163), Boca Raton, Florida

Saint Elizabeth Medical Center Edgewood ( Site 0165), Edgewood, Kentucky

University of Kentucky Chandler Medical Center ( Site 0158), Lexington, Kentucky

Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0133), Louisville, Kentucky

Louisiana State University Health Sciences Center New Orleans ( Site 0134), New Orleans, Louisiana

University of Maryland ( Site 0123), Baltimore, Maryland

Dana-Farber Cancer Institute-Lymphoma ( Site 0111), Boston, Massachusetts

University of Massachusetts Medical School ( Site 0119), Worcester, Massachusetts

St. Vincent Frontier Cancer Center-Research ( Site 0108), Billings, Montana

Atlantic Health System ( Site 0116), Morristown, New Jersey

New York Medical College ( Site 0113), Valhalla, New York

Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 0156), Nashville, Tennessee

Hospital Italiano de Buenos Aires ( Site 2203), Ciudad Autonoma de Buenos Aires, Buenos Aires

Instituto de Investigaciones Clínicas Mar del Plata ( Site 2205), Mar del Plata., Buenos Aires

Hospital Aleman ( Site 2200), Buenos Aites, Caba

Instituto Alexander Fleming ( Site 2201), Caba, Not set

Hospital Privado Universitario de Córdoba ( Site 2202), Cordoba, Not set

Townsville University Hospital ( Site 1800), Douglas, Queensland

Grampians Health ( Site 1802), Ballarat, Victoria

Royal Perth Hospital-Haematology ( Site 1801), Perth, Western Australia

Hospital Erasto Gaertner ( Site 2302), Curitiba, Parana

Liga Norte Riograndense Contra o Câncer ( Site 2305), Natal, Rio Grande Do Norte

Hospital Paulistano ( Site 2300), Sao Paulo, Not set

Pesquisa Clínica do Serviço de Hematologia do Hospital das Clínicas da FMUSP ( Site 2306), Sao Paulo, Not set

Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200), Toronto, Ontario

Biocenter ( Site 2401), Concepcion., Biobio

IC La Serena Research ( Site 2405), La Serena, Coquimbo

Oncocentro Valdivia ( Site 2407), Valdivia., Los Rios

FALP-UIDO ( Site 2400), Santiago., Region M. De Santiago

Clínica Inmunocel ( Site 2404), Santiago, Region M. De Santiago

Clínica RedSalud Vitacura ( Site 2409), Santiago, Region M. De Santiago

Bradfordhill ( Site 2403), Santiago, Region M. De Santiago

Beijing Cancer hospital ( Site 3000), Beijing, Beijing

Chongqing University Cancer Hospital-Medical Oncology ( Site 3025), Chongqing, Chongqing

Chongqing University Three Gorges Hospital ( Site 3026), Chongqing, Chongqing

Sun Yat-sen University Cancer Center-Internal Medicine ( Site 3001), Guangzhou, Guangdong

Zhujiang Hospital ( Site 3002), Guangzhou, Guangdong

The First Affiliated Hospital of Henan University of Science &Technology ( Site 3029), Luoyang, Henan

Henan Cancer Hospital-hematology department ( Site 3013), Zhengzhou, Henan

Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 3017), Wuhan, Hubei

The First Affiliated Hospital of Nanchang University ( Site 3004), Nanchang, Jiangxi

Jiangxi Provincial Cancer Hospital ( Site 3005), Nanchang, Jiangxi

The First Hospital of Jilin University-Hematology ( Site 3012), Changchun, Jilin

Fudan University Shanghai Cancer Center ( Site 3009), Shanghai, Shanghai

West China Hospital of Sichuan University-Head and Neck Oncology ( Site 3016), Cheng Du, Sichuan

Sichuan Cancer hospital-Oncology ( Site 3021), Chengdu, Sichuan

Zhejiang Cancer Hospital ( Site 3014), Hangzhou, Zhejiang

The First Affiliated Hospital Zhejiang University School of Medicine ( Site 3027), Hangzhou, Zhejiang

Hospital Pablo Tobon Uribe ( Site 0804), Medellin, Antioquia

Instituto Médico de Alta Tecnologia S.A.S ( Site 0803), Monteria, Cordoba

FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0801), Bogota, Distrito Capital De Bogota

Oncologos del Occidente ( Site 0800), Pereira., Risaralda

Fundacion Valle del Lili ( Site 0802), Cali, Valle Del Cauca

Hospital Metropolitano - Sede Lindora ( Site 2500), Santa Ana, San Jose

CIMCA ( Site 2501), San Jose, Not set

centre hospitalier lyon sud-Service Hématologie ( Site 0702), Pierre-Bénite, Rhone

Pitie Salpetriere University Hospital-Clinical haematology ( Site 0700), Paris, Not set

University Hospital of Alexandroupolis ( Site 0903), Alexandroupolis, Anatoliki Makedonia Kai Thraki

Evangelismos General Hospital of Athens ( Site 0900), Athens, Attiki

Regional General Hospital of Athens "Laiko" ( Site 0901), Athens, Attiki

MEDI-K ( Site 2602), Guatemala, Not set

Private Practice- Dr. Rixci Augusto Lenin Ramírez ( Site 2601), Guatemala, Not set

CELAN,S.A ( Site 2603), Guatemala, Not set

Queen Mary Hospital ( Site 3100), Hong Kong, Not set

Princess Margaret Hospital ( Site 3101), Hong Kong, Not set

Emek Medical Center-Hematology Unit ( Site 1102), Afula, Not set

Carmel Hospital ( Site 1103), Haifa, Not set

Hadassah Medical Center ( Site 1100), Jerusalem, Not set

Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1203), Rozzano, Milano

IRCCS - AOU di Bologna-Istituto di Ematologia "L. e A. Seragnoli" ( Site 1200), Bologna, Not set

Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1202), Napoli, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -ISTITUTO DI EMATOLOGIA ( Site 1204), Roma, Not set

Seoul National University Hospital-Oncology ( Site 0302), Seoul, Not set

Samsung Medical Center ( Site 0300), Seoul, Not set

Health Pharma Professional Research S.A. de C.V: ( Site 2700), Ciudad de Mexico, Distrito Federal

Medivest Centro de Investigación Integral ( Site 2704), Chihuahua, Not set

Centro de Infusion Superare ( Site 2701), Mexico City, Not set

Aotearoa Clinical Trials ( Site 0501), Auckland, Not set

Clínicas AUNA Sede Chiclayo ( Site 2803), Chiclayo, Lambayeque

Clínica San Felipe ( Site 2805), Lima, Not set

Hospital Nacional Edgardo Rebagliati Martins ( Site 2802), Lima, Not set

Specjalistyczny Szpital im. Dr Alfreda Sokolowskiego w Walbrzychu ( Site 1305), Walbrzych, Dolnoslaskie

Uniwersytecki Szpital Kliniczny-Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku ( Site 1301), Wroclaw, Dolnoslaskie

Centrum Onkologii Ziemi Lubelskiej-Oddzial Hematologii i Transplantacji Szpiku ( Site 1304), Lublin, Lubelskie

Pratia MCM Krakow ( Site 1303), Krakow, Malopolskie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( Site 1300), Warszawa, Mazowieckie

Szpitale Pomorskie Sp. z o. o.-Hematology and Bone Marrow Transplantation Department ( Site 1302), Gdynia, Pomorskie

Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku ( Site 1309), Słupsk, Pomorskie

Pratia Onkologia Katowice ( Site 1306), Katowice, Slaskie

Faculty of Medicine Siriraj Hospital-Division of Hematology, Department of Medicine ( Site 0400), Bangkok, Krung Thep Maha Nakhon

Chulalongkorn University ( Site 0402), Pathumwan, Krung Thep Maha Nakhon

Maharaj Nakorn Chiang Mai Hospital ( Site 0401), Chiang Mai, Not set

Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi ( Site 1912), Yenimahalle, Ankara

Ege University Medicine of Faculty ( Site 1902), Bornova, Izmir

Ankara University Hospital Cebeci-hematology ( Site 1901), Ankara, Not set

Mega Medipol-Hematology ( Site 1909), Istanbul, Not set

Dokuz Eylül Üniversitesi-Hematology ( Site 1905), Izmir, Not set

Ondokuz Mayıs Universitesi ( Site 1907), Samsun, Not set

MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2000), Cherkasy, Cherkaska Oblast

Communal non-profit enterprise "Regional clinical hospital of Ivano-Frankivsk Regional Council" ( Site 2004), Ivano-Frankivsk, Ivano-Frankivska Oblast

Institute of Blood Pathology and Transfusion Medicine AMS Ukraine ( Site 2002), Lviv, Lvivska Oblast

State non-profit enterprise National Cancer Institute ( Site 2001), Kyiv, Not set

National Research Center for Radiation Medicine of National Academy of Medical Sciences of Ukraine ( Site 2005), Kyiv, Not set

Public Non-Profit Enterprise Kyiv City Clinical Hospital #9 under the Executive Body of Kyiv City Co ( Site 2003), Kyiv, Not set

Aberdeen Royal Infirmary ( Site 2104), Aberdeen, Aberdeen City

The Royal Cornwall Hospital ( Site 2103), Truro, England

University College London Hospital-Cancer Clinical Trials Unit ( Site 2100), London-Camden, London, City Of

Conditions: DLBCL, Diffuse Large B-Cell Lymphoma

Learn More ›

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103

Recruiting

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.

Gender:

ALL

Ages:

Between 6 months and 25 years

Trial Updated:

07/18/2025

Locations: Children's Hospital Los Angeles ( Site 1006), Los Angeles, California +56 locations

Children's Hospital Los Angeles ( Site 1006), Los Angeles, California

Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016), Aurora, Colorado

Yale-New Haven Hospital ( Site 1012), New Haven, Connecticut

Johns Hopkins All Children's Hospital ( Site 1025), Saint Petersburg, Florida

University of Iowa-Holden Comprehensive Cancer Center ( Site 1017), Iowa City, Iowa

Dana-Farber Cancer Institute ( Site 1013), Boston, Massachusetts

Corewell Health ( Site 1001), Grand Rapids, Michigan

Children's Mercy Hospital ( Site 1024), Kansas City, Missouri

Rutgers Cancer Institute of New Jersey ( Site 1008), New Brunswick, New Jersey

New York Medical College ( Site 1023), Valhalla, New York

Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003), Fargo, North Dakota

Oregon Health and Science University ( Site 1004), Portland, Oregon

Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia, Pennsylvania

Sanford Children's Hospital-Sanford Children's Specialty Clinic ( Site 1015), Sioux Falls, South Dakota

University of Texas MD Anderson Cancer Center ( Site 1007), Houston, Texas

Intermountain - Primary Children's Hospital ( Site 1014), Salt Lake City, Utah

Sydney Children's Hospital-Kids Cancer Centre ( Site 1997), Randwick, New South Wales

Queensland Children's Hospital-Oncology & Haematology ( Site 1996), Brisbane, Queensland

UZ Gent ( Site 1428), Gent, Oost-Vlaanderen

Hospital Erasto Gaertner-CEPEP - Pesquisa Clínica ( Site 1268), Curitiba, Parana

Hospital de Clinicas de Porto Alegre ( Site 1265), Porto Alegre, Rio Grande Do Sul

Fundação Pio XII - Hospital de Câncer de Barretos ( Site 1264), Barretos, Sao Paulo

Fundação Faculdade Regional de Medicina de São José do Rio Preto-Centro Integrado de Pesquisa ( Site 1267), São José do Rio Preto, Sao Paulo

McGill University Health Centre-Pediatric HematologyOncology ( Site 1223), Montréal, Quebec

Hospital Carlos Van Buren ( Site 1880), Valparaíso, Valparaiso

Hospital Pablo Tobon Uribe ( Site 1923), Medellin, Antioquia

Clinica de la Costa S.A.S.-Clinical Research Oncology & Hematology -Pediatric ( Site 1924), Barranquilla, Atlantico

IMAT S.A.S ( Site 1921), Monteria, Cordoba

Rigshospitalet-Department of paediatrics and adolescent medicine, Section of Paed haem-onc ( Site 1467), Copenhagen, Hovedstaden

CHU de Bordeaux. Hopital Pellegrin ( Site 1105), Bordeaux, Aquitaine

Gustave Roussy ( Site 1103), Villejuif, Ile-de-France

Centre Hospitalier Universitaire de Nantes - Hôpital Femme-Enfant-Adolescent Chu De Nantes ( Site 1104), Nantes, Pays-de-la-Loire

Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone ( Site 1102), Marseille, Provence-Alpes-Cote-d Azur

CENTRE LEON BERARD-IHOPE (pediatrric oncology) ( Site 1100), Lyon, Rhone-Alpes

Universitätsklinikum Münster - Albert Schweitzer Campus-Pädiatrische Hämatologie und Onkologie ( Site 1141), Münster, Nordrhein-Westfalen

Aghia Sophia Children's Hospital-First Department of Pediatrics, National and Kapodistrian Universi ( Site 1797), Athens, Attiki

Semmelweis Egyetem ( Site 1838), Budapest, Not set

Rambam Health Care Campus-Pediatric Hemato-Oncology ( Site 1674), Haifa, Not set

Sheba Medical Center ( Site 1675), Ramat Gan, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori-Pediatric Oncology ( Site 1552), Milan, Lombardia

Ospedale Pediatrico Bambino Gesù IRCCS-Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica ( Site 1553), Rome, Roma

Seoul National University Hospital-Pediatrics ( Site 1972), Seoul, Not set

Asan Medical Center-Pediatrics - Pedicatric Oncology ( Site 1973), Seoul, Not set

Prinses Maxima Centrum voor Kinderoncologie ( Site 1510), Utrecht, Not set

Narodny ustav detskych chorob ( Site 1592), Bratislava, Bratislavsky Kraj

Hospital Sant Joan de Déu-Pediatric Oncology Department ( Site 1717), Esplugas De Llobregat, Barcelona

Hospital Infantil Universitario Niño Jesús-Servicio de Onco-Hematología Pediátrica ( Site 1715), Madrid, Madrid, Comunidad De

Hospital Universitari Vall d'Hebron-Servei de Hematologia i Oncologia Pediatrica ( Site 1716), Barcelona, Not set

Prövningsenhet barn, Sahlgrenska Universitetssjukhuset ( Site 1634), Gothenburg, Vastra Gotalands Lan

National Taiwan University Hospital ( Site 1983), Taipei, Not set

Hacettepe Universite Hastaneleri ( Site 1961), Ankara, Not set

Ankara Bilkent Şehir Hastanesi ( Site 1962), Ankara, Not set

Ege Universitesi Hastanesi ( Site 1963), İzmir, Not set

Royal Victoria Infirmary-Great North Children's Hospital ( Site 1348), Newcastle upon Tyne, England

University College London Hospital ( Site 1350), London, London, City Of

Royal Marsden Hospital (Sutton)-Drug Development Unit ( Site 1347), Sutton., Surrey

University Hospital of Wales ( Site 1346), Cardiff, Not set

Conditions: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma

Learn More ›

A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

NCT05660395

Recruiting

The primary objective of this study is to determine the recommended dosing regimen of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) participants with moderate and severe hepatic impairment.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/14/2025

Locations: The Oncology Institute of Hope & Innovation - Lynwood, Lynwood, California +13 locations

Conditions: Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma

Learn More ›

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

NCT04002947

Recruiting

Background: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis. Researchers want to add another drug to standard treatment see if it can improve the cure rate. Objective: To see if the drug acalabrutinib given with rituximab and standard combination chemotherapy can improve the cure rate of aggressive B-cell lymphomas such as diffuse large B-cell lymphoma. Eligibility: Pe... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/12/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Diffuse Large B-Cell Lymphoma, DLBCL, NHL, Non-Hodgkin's Lymphoma

Learn More ›

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

NCT05952024

Recruiting

The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard front line chemoimmunotherapy treatments.

Gender:

ALL

Ages:

Between 65 years and 99 years

Trial Updated:

06/25/2025

Locations: Research Site, La Jolla, California +51 locations

Research Site, La Jolla, California

Research Site, Orange, California

Research Site, Stamford, Connecticut

Research Site, Jacksonville, Florida

Research Site, Des Moines, Iowa

Research Site, Lexington, Kentucky

Research Site, Beltsville, Maryland

Research Site, Towson, Maryland

Research Site, Detroit, Michigan

Research Site, Sioux Falls, South Dakota

Research Site, Lubbock, Texas

Research Site, Olympia, Washington

Research Site, Tacoma, Washington

Research Site, Barretos, Not set

Research Site, Belo Horizonte, Not set

Research Site, Brasilia, Not set

Research Site, Campinas, Not set

Research Site, Curitiba, Not set

Research Site, Florianópolis, Not set

Research Site, Goiania, Not set

Research Site, Natal, Not set

Research Site, Porto Alegre, Not set

Research Site, Recife, Not set

Research Site, Ribeirão Preto, Not set

Research Site, Rio de Janeiro, Not set

Research Site, Sao Luis, Not set

Research Site, Sao Paulo, Not set

Research Site, Sorocaba, Not set

Research Site, São José do Rio Preto, Not set

Research Site, São Paulo, Not set

Research Site, Busan, Not set

Research Site, Daegu, Not set

Research Site, Gyeongsangnam-do, Not set

Research Site, Incheon, Not set

Research Site, Jeonju-si, Not set

Research Site, Seo-gu, Not set

Research Site, Seoul, Not set

Research Site, Suwon-si, Not set

Research Site, Ulsan, Not set

Research Site, San Juan, Not set

Conditions: Diffuse Large B-Cell Lymphoma

Learn More ›

A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

NCT05896163

Recruiting

The purpose of this study is to learn about the effects of two study medicines (maplirpacept \[PF-07901801\] and glofitamab) when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that is relapsed or is refractory. Relapsed means has returned after last treatment. Refractory means that it has not responded to last treatment. The two study medicines are given after a single dose of obinutuzumab which is the third study medicine. DLBCL is a type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. It develops when the body makes abnormal B lymphocytes. These lymphocytes are a type of white blood cell that normally help to fight infections. This study is seeking adult participants who: * Have histologically confirmed diagnosis of DLBCL * Have received at least two first lines of treatment for NHL. * Are unable or unwilling to undergo a stem cell transplant or CAR-T cell therapy. Stem cell transplant is a procedure in which a patient receives healthy blood-forming cells to replace their own stem cells that have been destroyed by treatment. A CAR-T therapy is a type of treatment in which a patient's T cells are changed in the laboratory so they will attack cancer cells. Everyone in this study will receive all three medicines at the study site by intravenous (IV) infusion which is given directly into a vein. The two study medicines (maplirpacept \[PF-07901801\] and glofitamab) will be given in 21-day cycles. At Cycle 0, participants will receive a single dose of obinutuzumab pre-treatment followed by two step-up doses of glofitamab. The combination of maplirpacept (PF-07901801) with glofitamab full dose will be administered for the first time at Cycle 1 Day 1. Maplirpacept (PF-07901801) will be given weekly for the first three cycles and then every three weeks. Glofitamab will be given every 3 weeks for approximately 9 months. Thereafter participants will continue to receive maplirpacept alone. Maplirpacept (PF-07901801) will be given at different doses to different participants. Everyone taking part will receive the same fixed doses of glofitamab and obinutuzumab studied in patients with DLBCL. The study will compare the experiences of people receiving different doses of maplirpacept (PF-07901801). This will help to determine what dose is safe and effective when given with the other 2 study medicines. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/24/2025

Locations: The University of Kansas Cancer Center ,Investigational Drug Services, Fairway, Kansas +26 locations

The University of Kansas Cancer Center ,Investigational Drug Services, Fairway, Kansas

The University of Kansas Clinical Research Center, Fairway, Kansas

The University of Kansas Hospital, Kansas City, Kansas

University of Kansas Hospital Cambridge North Tower A, Kansas City, Kansas

Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis, Minnesota

Siteman Cancer Center, Saint Louis, Missouri

Barnes-Jewish Hospital Parkview Tower, Saint Louis, Missouri

Barnes-Jewish Hospital, Saint Louis, Missouri

Washington University School of Medicine, Saint Louis, Missouri

Swedish Cancer Institute, Seattle, Washington

Swedish Medical Center, Seattle, Washington

Princess Alexandra Hospital, Brisbane, Queensland

Townsville Hospital and Health Service, Douglas, Queensland

Townsville University Hospital, Townsville, Queensland

St Vincent's Hospital Melbourne, Fitzroy, Victoria

Epworth Freemasons, Melbourne, Victoria

Slade Pharmacy, Richmond, Victoria

Sheba Medical Center, Ramat Gan, Hamerkaz

Rambam Health Care Campus, Haifa, Hatsafon

Sourasky Medical Center, Tel Aviv, Tell Abīb

Hadassah Medical Center, Jerusalem, Yerushalayim

Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Aichi

Shizuoka Cancer Center, Nagaizumi-cho, Shizuoka

National Hospital Organization Kyushu Cancer Center, Fukuoka, Not set

China Medical University Hospital, Taichung, Not set

National Taiwan University Hospital, Taipei, Not set

Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Not set

Conditions: Diffuse Large B-Cell Lymphoma

Learn More ›

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

NCT05455697

Recruiting

This phase I/II trial tests the safety of tafasitamab, retifanlimab, and rituximab (TRR) as a prephase treatment and in combination with standard therapy consisting off cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or polatuzumab vedotin, cyclophosphamide, doxorubicin, and prednisone (PolaCHP) in patients with untreated diffuse large B-cell lymphoma. Tafasitamab, retifanlimab, and rituximab are monoclonal antibodies. Tafasitamab binds to a protein called CD19, which is found... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/09/2025

Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

Conditions: Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma

Learn More ›

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

NCT06846463

Recruiting

This study is a single-arm, open label, non-randomized, phase 2 trial of zanubrutinib in patients with diffuse large B-cell lymphoma (DLBCL) who have an MYD88 L265P mutation, a CD79B mutation, a NOTCH1 truncation, or who are CD5+ by immunohistochemistry (IHC).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/27/2025

Locations: Virginia Commonwealth University, Richmond, Virginia

Conditions: Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma

Learn More ›

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

NCT03147885

Recruiting

This phase Ib/II trial is aimed at studying the combination of a drug named Selinexor (selective inhibitor of nuclear export) in combination with standard therapy for B cell Non-Hodgkin's lymphoma called R-CHOP. The investigators will establish maximum tolerated dose of Selinexor in combination with RCHOP and also study the efficacy of this combination for therapy of B cell Non-Hodgkin's lymphoma. Giving Selinexor plus chemotherapy may work better in treating patients with B cell non-Hodgkin lym... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/25/2025

Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

Conditions: Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Extranodal Marginal Zone Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Stage III Non-Hodgkin Lymphoma, Stage IV Non-Hodgkin Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma

Learn More ›

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

NCT06249191

Recruiting

This phase Ib/II clinical trial tests the safety, side effects, and effectiveness of mosunetuzumab with chemotherapy for the treatment of patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or diffuse large B cell lymphoma. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as mosunetuzumab, may help the bo... Read More

Gender:

ALL

Ages:

Between 18 years and 75 years

Trial Updated:

03/19/2025

Locations: OHSU Knight Cancer Institute, Portland, Oregon

Conditions: Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma

Learn More ›

13 - 24 of 33